NCT06225596 2026-04-22
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2/3 Active not recruiting
Clinical Trials
8 trialsNCT05092958 2026-04-21
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04071236 2026-04-17
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07110038 2026-04-16
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05327686 2026-04-08
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT04822350 2026-04-02
AVENANCE
Pfizer
Completed
NCT03815643 2026-03-31
Avelumab Program Rollover Study
EMD Serono
Phase 3 Active not recruiting
NCT05267626 2026-03-31
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting